Samsung Biologics, AstraZeneca Expand Collaboration To Include COVID-19, Cancer Therapy

Samsung Biologics Co Ltd said it would continue its partnership with AstraZeneca Plc AZN on manufacturing biopharmaceuticals.

  • According to Samsung, the production of drug substances and drug products is valued at about $380 million, up from the initial $331 million after the companies expanded the deal in May 2021.
  • Samsung Biologics said it would start to manufacture a cancer immunotherapy product from next year along with AstraZeneca's COVID-19 long-acting antibody (LAAB) combination, AZD7442.
  • Related Link: AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised.
  • Samsung Biologics CEO John Rim said, "We are delighted to continue expanding our strategic collaboration with AstraZeneca, a valuable partner we have witnessed first-hand to have a strong commitment to saving lives of patients."
  • Samsung Biologics is building an additional facility, Plant 4, upon completion of which will allow it to hold the world's largest biomanufacturing capacity of 620,000L.
  • It has also added a messenger RNA vaccine drug substance manufacturing suite to the current facility in Songdo, ready for operations within the earlier part of the year in 2022.
  • Price Action: AZN shares are up 0.59% at $54.90 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!